PBL Solutions Limited v AFT Pharmaceuticals Limited

Link copied
Case Copied 31 min read

IN THE HIGH COURT OF NEW ZEALAND AUCKLAND REGISTRY

I TE KŌTI MATUA O AOTEAROA TĀMAKI MAKAURAU ROHE

CIV-2020-404-801

[2023] NZHC 881

BETWEEN

PBL SOLUTIONS LIMITED

First Plaintiff

AFT ORPHAN PHARMACEUTICALS LIMITED
Second Plaintiff

AND

AFT PHARMACEUTICALS LIMITED

First Defendant

HARTLEY CAMPBELL ATKINSON

Second Defendant

Hearing: On the papers (submissions 30 March and 11 April 2023)

Appearances:

JS Cooper KC, TJ Lindsay and CD Brownlee for the Plaintiffs AS Ross KC, MC Smith and Y Lee for the Defendants

Judgment:

21 April 2023


JUDGMENT OF FITZGERALD J

[As to application to file further evidence after closure of case]


This judgment was delivered by me on 21 April 2023 at 2.00pm, pursuant to Rule 11.5 of the High Court Rules.

Registrar/Deputy Registrar

Date……………

Solicitors:      Lindsay & Francis, Auckland

Gilbert Walker, Auckland

To:J Cooper KC, Auckland A Ross KC, Auckland

PBL SOLUTIONS LTD v AFT PHARMACEUTICALS LTD [2023] NZHC 881 [21 April 2023]

Introduction

[1]    In this proceeding, the plaintiffs claim that the first plaintiff and the first defendant were in a joint venture relationship for the purpose of developing and commercialising orphan drugs.1 PBL Solutions Ltd (PBL) says that the joint venture arrangement gave rise to fiduciary obligations owed by AFT Pharmaceuticals Ltd (AFT) to PBL. PBL further says that in breach of those fiduciary obligations, and/or in breach of contract, AFT effectively “stole” from the joint venture an opportunity relating to a drug called “Pascomer”, and has proceeded to develop and commercialise Pascomer for its own benefit.

[2]    The primary relief sought by PBL is its proportionate share of an account of the future profits expected to be earned by AFT from Pascomer – valued and discounted to enable a “lump sum” payment to be made now.2 In the alternative (though very much advanced as a secondary claim), PBL seeks its proportionate share of future profits actually earned by AFT from Pascomer (as and when they are earned).3 The quantum claimed is substantial, though so too is the extent of dispute between the parties about that sum. PBL seeks an account of profits (based on its view as to the net present value of the Pascomer opportunity) of between US$53 million and US$67 million. Conversely, in addition to denying liability, AFT says that the net present value of Pascomer is virtually nil, or is indeed a negative figure.

[3]    The claim is of some complexity, particularly in relation to quantum. The hearing took place over the period 31 October 2022 to 18 November 2022, and then a further two days of closing submissions on 8 and 9 December 2022.

[4]    Part of the alleged value of the Pascomer opportunity turns on the likelihood of the drug receiving regulatory approval for marketing and sale in  two  key  markets — the US and the European Union (the EU). Also relevant to that value is the timing of a competitor’s product (“Hyftor”, developed by Nobelpharma) receiving approval in those markets. This is because once an orphan drug is approved, it will


1      “Orphan…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read PBL Solutions Limited v AFT Pharmaceuticals Limited and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2023] NZHC 881
Decision Date

CaseChat Overview and Summary

PBL Solutions Limited and AFT Orphan Pharmaceuticals Limited brought claims against AFT Pharmaceuticals Limited and Hartley Campbell Atkinson for breach of fiduciary duties and/or contract in relation to the development and commercialisation of orphan drugs. The plaintiffs sought an account of profits relating to a drug called "Pascomer". The defendants sought leave to file further evidence and make additional submissions in relation to the prospects of Pascomer being approved for marketing and sale in the EU and the appropriate discount rate. The court considered the principles of admitting further evidence under section 98 of the Evidence Act 2006, including the discretion of the court, the justice of the case, and the potential unfairness to the other party. The court concluded that the proposed new evidence relating to the EMA's opinion on Hyftor and the updated Damodaran data was not admissible, as it related to contingencies that were expressly considered at trial and it would be unfair to the plaintiffs to admit the evidence post-trial. The application for leave to file further evidence and make additional submissions was therefore declined.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.